Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton

Cancer Research

Volumn 68, Issue 15, 2008, Pages 6241-6250

  Barkan, Dalit ^a   Kleinman, Hynda ^b   Simmons, Justin L ^a   Asmussen, Holly ^a   Kamaraju, Anil K ^a   Hoenorhoff, Mark J ^a   Liu, Zi Yao ^a   Costes, Sylvain V ^c   Cho, Edward H ^a   Lockett, Stephen ^a   Khanna, Chand ^a   Chambers, Ann F ^d   Green, Jeffrey E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; F ACTIN; FIBRONECTIN; MYOSIN LIGHT CHAIN KINASE; PROTEIN P27; MYOSIN LIGHT CHAIN; PRIMER DNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL CULTURE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CYTOSKELETON; EPIGENETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRESS FIBER; TUMOR CELL; ANIMAL; CELL CYCLE; CELL DIVISION; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; METASTASIS; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSKELETON; DNA PRIMERS; ENZYME ACTIVATION; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; MICE; MYOSIN LIGHT CHAINS; MYOSIN-LIGHT-CHAIN KINASE; NEOPLASM METASTASIS; PHOSPHORYLATION;

EID: 51049119424     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6849     Document Type: Article

References (45)

1. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419-24.
2. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
3. Demicheli R. Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 2001;11:297-306.
4. Goldberg SF, Harms JF, Quon K, Welch DR. Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis 1999;17:601-7.
5. Naumov GN, MacDonald IC, Weinmeister PM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002;62:2162-8.
6. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46.
7. Naumov GN, Townson JL, MacDonald IC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003;82:199-206.
8. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-25.
9. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002;70:498-505.
10. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002;70:537-46.
11. Gassmann P, Enns A, Haier J. Role of tumor cell adhesion and migration in organ-specific metastasis formation. Onkologie 2004;27:577-82.
12. Nelson CM, Bissell MJ. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol 2005;15:342-52.
13. Shaw KR, Wrobel CN, Brugge JS. Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 2004;9:297-310.
14. Morris VL, Koop S, MacDonald IC, et al. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin Exp Metastasis 1994;12:357-67.
15. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
16. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-6.
17. Harms JF, Budgeon LR, Christensen ND, Welch DR. Maintaining GFP tissue fluorescence through bone decalcification and long-term storage. Biotechniques 2002;33:1197-200.
18. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003;30:256-68.
19. Ventura A, Meissner A, Dillon CP, et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A 2004;101:10380-5.
20. Morris VL, Tuck AB, Wilson SM, Percy D, Chambers AF. Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clin Exp Metastasis 1993;11:103-12.
21. Thompson EW, Brunner N, Torri J, et al. The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis 1993;11:15-26.
22. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997;137:481-92.
23. Saitoh M, Ishikawa T, Matsushima S, Naka M, Hidaka H. Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. J Biol Chem 1987;262:7796-801.
24. Nairn AC, Picciotto MR. Calcium/calmodulin-dependent protein kinases. Semin Cancer Biol 1994;5:295-303.
25. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
26. Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET. Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res 2004;64:5973-81.
27. Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A 2000;97:10026-31.
28. Roth JM, Akalu A, Zelmanovich A, et al. Recombinant α2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Am J Pathol 2005;166:901-11.
29. Paszek MJ, Zahir N, Johnson KR, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005;8:241-54.
30. Huang S, Ingber DE. Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. Exp Cell Res 2000;261:91-103.
31. Folkman J, Moscona A. Role of cell shape in growth control. Nature 1978;273:345-9.
32. Defilippi P, Olivo C, Venturino M, Dolce L, Silengo L, Tarone G. Actin cytoskeleton organization in response to integrin-mediated adhesion. Microsc Res Tech 1999;47:67-78.
33. Tang Y, Olufemi L, Wang MT, Nie D. Role of Rho GTPases in breast cancer. Front Biosci 2008;13:759-76.
34. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 1994;372:231-6.
35. Minamiya Y, Nakagawa T, Saito H, et al. Increased expression of myosin light chain kinase mRNA is related to metastasis in non-small cell lung cancer. Tumour Biol 2005;26:153-7.
36. Kaneko K, Satoh K, Masamune A, Satoh A, Shimosegawa T. Myosin light chain kinase inhibitors can block invasion and adhesion of human pancreatic cancer cell lines. Pancreas 2002;24:34-41.
37. Fazal F, Gu L, Ihnatovych I, et al. Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo. Mol Cell Biol 2005;25:6259-66.
38. Feng Y, Sun B, Li X, et al. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat 2007;103:319-29.
39. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 2006;66:11089-93.
40. Larsen M, Artym VV, Green JA, Yamada KM. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 2006;18:463-71.
41. Weaver VM, Petersen OW, Wang F, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997;137:231-45.
42. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89-104.
43. Korah R, Boots M, Wieder R. Integrin α5β1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 2004;64:4514-22.
44. Walker JL, Fournier AK, Assoian RK. Regulation of growth factor signaling and cell cycle progression by cell adhesion and adhesion-dependent changes in cellular tension. Cytokine Growth Factor Rev 2005;16:395-405.
45. White DE, Kurpios NA, Zuo D, et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004;6:159-70.